Join the CannMed Capital Markets Workshop
Monday, May 13th, Marco Island, FL

This workshop is an interactive discussion on the status of the global capital market for Cannabis and Cannabiniod innovation. The panels and speakers will address the historical context, what are current issues and what lies ahead for the future so companies and technology practitioners can effectively and proactively drive global innovation in the sector.

Image
Image
Image

Program Overview

This workshop will be led by David Traylor, a Senior Managing Director at Golden Eagle Partners. The Capital Markets Workshop includes a half-day interactive discussion on Monday, May 13th, allowing participants to attend the main conference that takes place on May 14th & 15th. This workshop is going to explore a global perspective of the hurdles, issues and concepts around funding cannabinoid and cannabis innovation.

Capital Markets Workshop Participants

Headshot of David Traylor

David Traylor
Senior Managing Director
Golden Eagle Partners
VIEW BIO

Headshot of Matt Daugherty

Matt Daugherty
Director
Golden Eagle Partners
VIEW BIO

Headshot of Ethan Russo

Ethan Russo, MD
Founder/CEO
CReDO Science
VIEW BIO

Headshot of Debra Kimless

Debra Kimless, MD
Chief Medical Officer
PG Pharma

VIEW BIO

Headshot of Trevor Shewfelt

Trevor Shewfelt, BSc, BSc Pharm, CRE
Pharmacist
Dauphin Clinic Pharmacy
VIEW BIO

Headshot of Eric Berlin

Eric Berlin, J.D.
Leader of Cannabis Group
Dentons US
VIEW BIO

Headshot of Hunter Land

Hunter Land, PhD
VP, Research & Development
Biopharmaceutical Research Company
VIEW BIO

Headshot of Benjamin Cameransi

Benjamin Cameransi, MD
Managing Partner
Mingowood Pharmacal, LLC
VIEW BIO

Headshot of Loren DeFalco

Loren DeFalco
Partner
CB1 Capital
VIEW BIO

Headshot of Charles Farkas

Charles Farkas
Chairman of the Board
Medicinal Genomics
VIEW BIO

Headshot of Jason Moscovici

Jason Moscovici
President, Principal
Provisions Legal
VIEW BIO

Headshot of Kevin McKernan

Kevin McKernan
Chief Scientific Officer
Medicinal Genomics
VIEW BIO

Headshot of Travis Higginbotham

Travis Higginbotham
Founder & CEO
Due Diligence Horticulture, LLC
VIEW BIO

Headshot of Drew Hull

Drew Hull
Director of Government Affairs
True Terpenes

Headshot of Drew Hull

Dustin Sulak, DO
Co-Founder & Medical Director
Healer.com
VIEW BIO

Capital Markets Participants

Headshot of David Traylor

David Traylor
Senior Managing Director

Golden Eagle Partners
VIEW BIO

Headshot of Matt Daugherty

Matt Daugherty
Senior Vice President
Golden Eagle Partners

Headshot of Charles Farkas

Charles Farkas
Chairman of The Board
Medicinal Genomics
VIEW BIO

Headshot of Kevin McKernan

Kevin McKernan
Chief Scientific Officer
Medicinal Genomics
VIEW BIO

Headshot of Oliver Cruze

David Meiri, PhD
Laboratory of Cancer Biology & Cannabinoid Research - Technion
VIEW BIO

Headshot of Ethan Russo

Ethan Russo, MD
Founder/CEO

CReDO Science
VIEW BIO

Headshot of Debra Kimless

Debra Kimless, MD
Chief Medical Officer
PG Pharma
VIEW BIO

Headshot of Hunter Land

Hunter Land, PhD
VP, Research & Development
Biopharmaceutical Research Company
VIEW BIO

Headshot of Jeffrey Raber

Jeffrey Raber, PhD
Chief Executive Officer
The Werc Shop
VIEW BIO

Headshot of David Neundorfer

David Neundorfer
Chief Executive Officer

Open Book Extracts
VIEW BIO

Headshot of Loren DeFalco

Loren DeFalco
Partner
Director of Research

CB1 Capital Management
VIEW BIO

Headshot of Elena Mervine

Elena Mervine
Partner
CohnReznick Advisory - Transaction Advisory Services
VIEW BIO

Headshot of Eric Berlin

Eric Berlin
Partner
Co-Head Cannabis Group
VIEW BIO

Headshot of David Kerr

David S. Kerr
Partner and Co-Founder
Berg Hill Greenleaf Ruscitti’s Intellectual Property Practice Group
VIEW BIO

Headshot of Oliver Cruze

Oliver Kruze
Chief Executive Officer

Tikun Olam USA
VIEW BIO

Headshot of Len May

Len May, MSc.
CEO & Co-Founder

Endocanna Health, Inc.
VIEW BIO

Headshot of Lisa Rich-Milan

Lisa Rich-Milan
Chief Executive Officer

Maridose LLC
VIEW BIO

Headshot of Trevor Shewfelt

Trevor Shewfelt, BSc. Pharm, CRE
Pharmacist

Dauphin Clinic Pharmacy
VIEW BIO

Headshot of Trevor Shewfelt

Jill Ellsworth MS, RDN
Founder & CEO

Willow Industries
VIEW BIO

Headshot of Ben Boo

Ben Boo
VP of Cultivation
Vireo Health
VIEW BIO

Headshot of Bruce Mackler

Bruce F Mackler Ph.D., J.,D.
Chairman of the Board / Co-Founder
Ethicann Pharmaceuticals Inc
VIEW BIO

Headshot of Scott Thorn

Scott Thorn
Co-Founder & COO
Open Book Extracts
VIEW BIO

Headshot of Douglas Hannah

Douglas Hannah
Partner
Silverleaf Venture Partners
VIEW BIO

Headshot of David Engel

David Engel
CEO/President
Full Moon Investments

Capital Markets Workshop Schedule

Monday, May 13th, 2024 / 8:30 AM - 11:45 AM
SPONSORED BY:
golden eagle partners logo white

8:30 AM -  Funding Innovation in Cannabis
Charles Farkas, Loren DeFalco, Matt Daugherty

9:00 AM -  Cannabis Intellectual Property: A Moving Target
Benjamin Cameransi, Kevin McKernan, Jason Moscovici

  • Is the history of IP in biotechnology a good comparison for cannabis IP?
  • What are the current precedents for IP in cannabis?
  • What will be the role of IP in the near- and long-term future of cannabis?

9:30 AM - Perspectives on Production: Cultivation, Chemistry and More
Trevor Shewfelt, Travis Higginbotham

  • Some technologies that have been proven to be valuable to cannabis cultivation
  • How will cultivation be applied in the future
  • Is there different/optimal ways to produce different molecules?

10:00 AM - Break

10:15 AM - Molecules, the Future of Cannabis?
Dustin Sulak, Drew Hull

10:45 AM -  Implications on Cannabis Rescheduling: Now and in the Future
Hunter Land, David Traylor, Eric Berlin, Ethan Russo

  • Will reschedule happen and when?
  • What are the positive and negative outcomes if Cannabis is rescheduled to Schedule 3?
  • Who will benefit the most and who will not benefit the most of the rescheduling to Schedule 3?

11:15 AM - Cannabis and Cannabinoids: Where to From Here?
Ethan Russo, Hunter Land, Debra Kimless, David Traylor

  • What are some good examples of previous inflection points in cannabis?
  • Does cannabis have more frequent inflection points and can they be planned for?
  • Can the management of technology inflection points be a competitive advantage?

ATTENDANCE IS LIMITED. THE OPPORTUNITIES ARE NOT.

Image